Investor Relations

GeneNews Limited
2 East Beaver Creek Road, Building 2
Richmond Hill, Ontario, Canada
L4B 2N3

Phone: (905) 739-2030
Toll Free: 1-866-375-0442
Fax: (905) 739-2031
E-mail: contact@genenews.com

Key Statistics
Industry: Biotechnology
Segment: Genomics
Ownership: Public
Exchange: TSX
Symbol: GEN

Description

Founded in 1998, GeneNews is a biotechnology company focused on applying the Sentinel Principle to develop and commercialize novel blood-based molecular diagnostic tests in cancer, cardiovascular disease, central nervous system disorders, psychiatric disorders and arthritis. GeneNews is developing specific diagnostic tests in these areas that address critical unmet clinical needs, while at the same time delivering significant healthcare and economic benefits. The first tests under development are tests for colorectal cancer and prostate cancer. The Sentinel Principle is a powerful enabling technology for identifying and developing blood-based biomarkers which will eventually lead to the delivery of Personalized Health Management.

home-side

Testimonials

"Patients in general, want to avoid colonoscopy both because of the procedure itself and the bowel preparation necessary. Two years ago a blood test became available to we physicians in Toronto which greatly facilitates the understanding of the potential for cancer of the colon and the advice we give to our patients when screening for colorectal cancer. ColonSentry is now incorporated into the blood draw associated with an annual physical, when appropriate."

Dr. Ron Porter,,
Medical Director, Virtual Wellness Institute, Toronto, Ontario.
v-w-i.com

Latest Press Releases

Dec 23	GeneNews Extends Term of Certain Warrants
Nov 10	GeneNews' Sentinel Principle® Used to Discover New Blood Based Biomarkers for Nasopharyngeal Carcinoma
Nov 9	GeneNews Diagnostics Launches ColonSentry in Malaysia
Oct 31	GeneNews Shareholders Approve Proposed Share Consolidation

Learn More »

Search

Public

Investor Relations

Description